Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) have earned an average rating of "Buy" from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $20.33.
A number of equities analysts recently commented on the company. Lifesci Capital reissued an "outperform" rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, December 21st. Jefferies Financial Group started coverage on MoonLake Immunotherapeutics in a report on Friday, November 11th. They issued a "buy" rating and a $16.00 price target on the stock.
Get MoonLake Immunotherapeutics alerts:MoonLake Immunotherapeutics Stock Up 3.4 %
Shares of NASDAQ:MLTX opened at $12.29 on Wednesday. MoonLake Immunotherapeutics has a 1 year low of $4.25 and a 1 year high of $15.19. The stock's fifty day moving average price is $9.98 and its 200-day moving average price is $8.31.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. On average, analysts forecast that MoonLake Immunotherapeutics will post -1.4 EPS for the current year.Hedge Funds Weigh In On MoonLake Immunotherapeutics
Several institutional investors and hedge funds have recently modified their holdings of MLTX. UBS Group AG boosted its holdings in shares of MoonLake Immunotherapeutics by 2.7% during the 3rd quarter. UBS Group AG now owns 75,664 shares of the company's stock worth $587,000 after purchasing an additional 2,004 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of MoonLake Immunotherapeutics during the second quarter worth $62,000. Cowen AND Company LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the second quarter worth $85,000. Meridian Wealth Management LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the second quarter worth $142,000. Finally, Millennium Management LLC purchased a new position in MoonLake Immunotherapeutics in the second quarter valued at $147,000. Hedge funds and other institutional investors own 76.13% of the company's stock.
MoonLake Immunotherapeutics Company Profile
(Get Rating)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
Featured Articles
- Get a free copy of the StockNews.com research report on MoonLake Immunotherapeutics (MLTX)
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Tritium Is the Largest DC EV Charger Maker You've Never Heard Of
- Thor Industries Hammered Its Numbers. Is it a Buy?
- United Airlines Soars Ahead of Earnings...Time to Deplane?
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.